Skip to content

MPN Treatments & Resources

If you are diagnosed with MPN, go get help! Browse our resources. We are here for you.

Understanding MPNs

MPNs are classified by the World Health Organization (WHO) as blood cancers because blood cells are produced in an uncontrolled way.

MPN Cancer Connection

a resource for MPN patients

Information. Community. Opportunity.

Welcome to MPN Cancer Connection, where the future is bright for the MPN community, filled with opportunity with new clinical trial treatments, offering a wide range of MPN resources and information, all for improved patient care and quality of life.

MPN-CC was founded to serve patients, care partners, physicians, and your healthcare team. We help empower patients to be proactive and to be your own health advocate by asking questions from your healthcare team.

Clinical Trial Finder

Free, No Personal Information Required

Search for MPN Clinical Trials that may help you find new treatments and medical approaches for your myelofibrosis (MF), polycythemia vera (PV) or essential thrombocythemia (ET). is difficult to use for patients, as it is primarily a resource for doctors and clinicians. Our Clinical Trial Finder restructures the trial information – providing “easy access” while improving patient’s understanding of the trial.

David Wallace

MPN Cancer Connection, CEO and Founder

David Wallace is honored to receive the Cure Magazine 2016 MPN Hero Award for his commitment to the broader MPN community for his work on PV Reporter founded in 2013 and MPN Cancer Connection, a non-profit organization founded in 2015. He is committed to helping newly diagnosed patients with myeloproliferative neoplasms (MPNs) learn more about their condition. He shares his experience as an “outspoken patient advocate” to help fellow patients get up to speed quickly and have the tools necessary to make educated decisions on treatment options.

Dr. Ruben Mesa

Executive Director, Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center

Listen as Dr. Ruben Mesa provides a MPN Update Summer 2021 on disease burden, current treatments, and new therapies in developments (including clinical trials) on the myeloproliferative neoplasms (MPNs) including Systemic Mast Cell Disease (SM), essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). Ruben Mesa, M.D. is the Executive Director of Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center.

Industry Partners

error: Content is protected !!

Site by: Kaleidoscopic

Malcare WordPress Security